GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction

Image of GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial
infarction

PRODUCT LITERATURE

GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction

GRUPPO ITALIANO PER LO STUDIO DELLA SOPRAVVIVENZA NELL’INFARTO MIOCARDICO - Personal Name;

A multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1·5 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were also randomised to receive heparin (12 500 U subcutaneously twice daily until discharge from hospital, starting 12 h after beginning the tPA or SK infusion) or usual therapy.

Availability

Location name is not set Location name is not set

Fibrion-005

Available

Detail Information

Series Title: -
Call Number: -
Publisher: : .,
Collation: -
Language: English
ISBN/ISSN: -
Classification: NONE
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Fibrion
Specific Detail Info: Lancet 1990
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

Read Here

Comments

You must be logged in to post a comment